Stay updated on INO-5401+INO-9012+Atezolizumab in Urothelial Carcinoma Clinical Trial
Sign up to get notified when there's something new on the INO-5401+INO-9012+Atezolizumab in Urothelial Carcinoma Clinical Trial page.

Latest updates to the INO-5401+INO-9012+Atezolizumab in Urothelial Carcinoma Clinical Trial page
- Check3 days agoNo Change Detected
- Check11 days agoChange DetectedThe page reorganizes the study site locations by introducing a consolidated 'Locations' section and removing individual 'Arizona Locations', 'Florida Locations', etc., while listing the states under the new section. A new revision tag v3.3.3 is added.SummaryDifference1%

- Check18 days agoNo Change Detected
- Check25 days agoNo Change Detected
- Check39 days agoChange DetectedThe page revision history shows Revision: v3.3.2 added and Revision: v3.2.0 removed, indicating a small metadata update.SummaryDifference0.1%

- Check46 days agoChange DetectedRemoved a generic government funding/status notice about site operations; this affects only site-wide messaging and not the study details or enrollment information.SummaryDifference0.4%

- Check61 days agoChange DetectedThe study status is updated to Completed. Enrollment is 35 participants across 11 locations, with a primary completion date of 2025-05-09.SummaryDifference0.4%

- Check90 days agoChange DetectedKey updates: version bump to v3.2.0 and an important government-operating-status notice; the previous v3.1.0 reference was removed. Overall, user-facing status and versioning information were updated. If no other content changed, this is a targeted update to status and versioning.SummaryDifference3%

- Check97 days agoChange DetectedVersion updated from v3.0.2 to v3.1.0; no substantive content changes detected.SummaryDifference0.1%

Stay in the know with updates to INO-5401+INO-9012+Atezolizumab in Urothelial Carcinoma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the INO-5401+INO-9012+Atezolizumab in Urothelial Carcinoma Clinical Trial page.